Trial · NCT06344442
Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
NCT06344442, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial). Trials, record NCT06344442. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06344442
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Low-dose Arginine-vasopressin Supplementation on Post-transplant Acute Kidney Injury After Liver Transplantation (AVENIR Trial)
- NCT number
- NCT06344442
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 304 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Acute Kidney Injury Post Liver Transplantation
- Interventions
- Arginine vasopressin, Norepinephrine
- First posted
- 2024-04-03
- Last updated
- 2026-02-05
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary objective is to compare the effect of intraoperative low-dose supplementation of AVP vs norepinephrine infusions on post-transplant Acute Kidney Injury after liver transplantation. | during the first 7 postoperative days | The stages of AKI according to AKI Network criteria (KDIGO score) determined by changes in serum creatinine and changes in urine output. |
| Secondary | To compare into the two arms the number of packed red blood cellsand fresh frozen plasma transfused | during the first 12 hours postoperatively | |
| Secondary | To compare into the two arms the number of the Number of AKI KDIGO 1 | 1 during the first 7days | defined as increase in serum creatinine concentration by 1.5 to 1.9 fold or ≥0.3mg/dl (or 27 micromol/L) within 48h or urine output \<0.5 ml/Kg/h over a period 6-12 h) |
| Secondary | To compare into the two arms the Number of AKI KDIGO 2 | during the first 7 postoperative | defined as increase in serum creatinine concentration by 2.0 to 2.9 fold or urine output \<0.5 ml/Kg/h over a period ≥12 h) |
| Secondary | To compare into the Number of AKI KDIGO 3 | during the first 7 postoperative | defined as increase in serum creatinine concentration ≥ 3 fold or ≥ 4mg/dl (or 354 micromol/L) or urine output \<0.3 ml/Kg/h for ≥24h or anuria\>12h) |
| Secondary | The need for renal replacement for replacement therapy (RRT) in ICU | during the first 7 days postoperatively and on postoperative day 30 | |
| Secondary | The number of patients remaining on dialysis at the end of the study | on the 30th Day | |
| Secondary | Average intraoperative norepinephrine concentrations | intraoperative | |
| Secondary | Average intraoperative concentrations of other vasopressors and inotropes (Adrenalin, Dobutamine) | intraoperative | |
| Secondary | Number of platelets transfused intraoperatively | during the first 12 hours postoperatively. |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers13
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06344442
GET https://conductscience.org/api/trials/v1/NCT06344442/registered